


Mission: The prevention of blindness and the early detection and treatment of multiple systemic and ocular diseases


RetinalGenix Technologies Inc. (OTCQB: RTGN) RetinalGenix is an ophthalmic research and development company seeking to revolutionize early disease detection and improve patient outcomes across multiple disease areas by integrating genetic screening, advanced imaging, and therapeutic development. Its proprietary High-Resolution Retinal Imaging and RetinalGenix DNA/RNA/GPS Pharmaco-Genetic Mapping™ technologies are designed to help prevent blindness by detecting initial physiological changes that could indicate future ocular and systemic diseases affecting neurodegenerative, cardiovascular, vascular, and metabolic systems, as well as diabetic conditions, Alzheimer's disease and Parkinson's disease. RetinalGenix is also developing therapeutic drugs for dry age-related macular degeneration (dry AMD) and Alzheimer's disease/dementia.

3 Core Technologies




Proprietary Advanced Hardware

RetinalCam™ high-resolution real-time retinal and ocular imaging and monitoring connects patients with the proprietary eye-specialty provider network and is available for patient/doctor use 24/7



Genetic Biomarkers & Therapeutics

Genetic Virtual Test: Non-invasive, cost-effective evaluation of patient's disease risk profile via DNA and RNA biomarkers



RetinalGenix DNA/RNA/GPS™ Pharmaco-Genetic Mapping™

Software to validate and guide the development of novel methods and therapeutic products

Investment Highlights



Remote monitoring device patented to assist in the diagnosis of systemic and ocular disease and prevent blindness

- Soon to be commercialized



\$10B market opportunity (AMD and Alzheimer's alone)¹



New drug development enhancing the portfolio of drugs and investigating alternative uses



Advancement of early diagnosis and treatment of systemic and ocular diseases AMD, Alzheimer's, cancer, diabetes, heart disease, HIV, hypertension, stroke, etc.



Industry-leading medical and advisory team with 100+ years of experience in the field



Significant demand for the Company's product satisfying huge unmet needs



RetinalGenix DNA/RNA/GPS virtual test provides a **non-invasive and cost-effective** way to evaluate a patient's disease risk profile



Planned Nasdaq uplisting - raising capital to complete product development; after securing the funds, Company will apply to uplist on Nasdaq

¹) Source: Management estimate

RetinalCam™

- The technology costs far less than expensive diagnostic methods such as MRI, CT and PET scans, ultrasound, echocardiogram, blood draws at specialty labs, retinal testing, and others
- Patented real-time monitoring, imaging, and physician alert system device incorporating a high-resolution ocular camera with video streaming capabilities allowing examination of the central 40° of the retina that can detect early signs of retinal and systemic disease without pupil dilation
- The device will be affordable, easy-to-use by not only eye care professionals, but by all other medical specialties
- Projecting the device to complete testing by Q4 2025

RetinalGeniX DNA/RNA/ GPS Pharmaco-Genetic Mapping™

RetinalGeniX DNA/RNA/GPS Pharmaco-Genetic Mapping™ combined with proprietary patented high-resolution 24/7 real-time retinal imaging technology can enable the detection of the earliest signs of eye and systemic diseases more efficiently and effectively.

- *May facilitate the detection of early physiologic changes that may represent biomarkers useful for the detection of blindness or systemic diseases*
- *Combined with RetinalCam™ is the basis for therapeutic drug development*



Drug Therapeutics

RetinalGenix is expanding its reach into diagnostics and therapeutics and plans to use its pharmacogenetic mapping RetinalGeniX DNA-GPS™ and high-resolution imaging RetinalCam™ to validate and guide the development of novel methods and therapeutic products. 2 drug repositioning therapies in development:

- **RTG 2023:** Clinical drug formulation for the treatment of dry age-related macular degeneration (dry AMD)
- **RTG 2024:** Clinical drug formulation for the treatment of Alzheimer's and dementia

Market Opportunity:

\$13.7B by 2030 (Alzheimer's)¹

\$18.3B by 2023 (AMD)²

1) Insights10.com; North America Alzheimer's disease drugs market analysis. 2) Source: Global Age-Related Macular Degeneration Market Forecast Report by Disease Type, Product Distribution Channel, Countries, and Company Analysis, 2024-2032

Experienced Management

Jerry Katzman, MD

Chairman, President & CEO

- Eye MD surgeon 25+ years of experience and who has performed the most advanced surgical procedures and techniques used in cataract and refractive surgery and a myriad of general ophthalmology procedures
- Co-Founder President, BOD - EyeCare International. The largest national discount vision network with over 13,000 locations. Expanded to include optometry, audiology, pharmacy, and chiropractic medicine
- CEO and President of Clinical Control Systems, Inc
- Chief Medical Officer and BOD - Amacore Group, Inc
- BS Biomedical Engineering, Boston University, M.D. degree Universidad de Guadalajara, Internal Medicine and residency in Ophthalmology at the Albert Einstein Colleg (Bronx Lebanon Hospital Center)

Stephen Tannenbaum

Business Advisor

- Advised companies and closed transactions across a spectrum of industries, including infrastructure, TMT, healthcare, SPACs, pharmaceuticals, cannabis, and more on strategic and financial opportunities, including M&A, equity, debt capital markets, IPOs, and SPACs
- Unique specialization in pharmaceuticals and cannabis, taking part in raising over \$1.5B for businesses in a rapidly changing industry
- Accomplished performance history in capital markets transactions for public and private companies in special situations, working closely in story-driven capital raises, leveraging resources and knowledge to provide thoughtful and actionable advice
- Graduated with a BS in Economics from The Wharton School of The University of Pennsylvania with honors

Market Snapshot

Share Price

\$3.54 (9/8/25)

Shares O/S

18.6M

Market Cap

\$65.8M

RetinalGenix Technologies Inc. | 409 Apollo Beach Blvd, Ste 6, Apollo Beach, FL 33572

Investor Relations Contact | 800-331-5446 | ir@retinalgenix.com | retinalgenix.com

Price quotes from OTC Markets

Forward-Looking Statements: This fact sheet contains certain forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified by the use of the words "could," "believe," "anticipate," "intend," "estimate," "expect," "may," "continue," "predict," "potential," "project" and similar expressions that are intended to identify forward-looking statements and include statements. All forward-looking statements speak only as of the date of this fact sheet. You should not place undue reliance on these forward-looking statements. Although the Company believes that its plans, objectives, expectations and intentions reflected in or suggested by the forward-looking statements are reasonable, the Company can give no assurance that these plans, objectives, expectations or intentions will be achieved. Forward-looking statements involve significant risks and uncertainties (some of which are beyond the Company's control), assumptions and other factors that could cause actual results to differ materially from historical experience and present expectations or projections. Actual results may differ materially from those in the forward-looking statements and the trading price for the Company's common stock may fluctuate significantly. Forward-looking statements also are affected by the risk factors described in the Company's filings with the SEC. Except as required by law, the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. The information in this fact sheet is provided only as of the date of this fact sheet, and we undertake no obligation to update any forward-looking statements contained in this fact sheet on account of new information, future events, or otherwise, except as required by law.